OtoNexus Medical Technologies
Transforming Otitis Media Diagnosis through Ultrasound Technology

Antibiotic overuse is a pressing issue in pediatric healthcare. Despite guidance from organizations like the CDC and the American Academy of Pediatrics (AAP), approximately 85% of children diagnosed with otitis media—commonly known as a middle ear infection—are still prescribed antibiotics, even though most cases are viral and do not require such treatment.

OtoNexus Medical Technologies addresses this issue with NOVOSCOPE^®, a revolutionary ear ultrasound otoscope. The handheld, AI-powered ear ultrasound otoscope uses a proprietary new ultrasound technology technique to provide precise, objective data about the type of middle ear infection. The device delivers real-time data, identifying whether fluid is present and, crucially, differentiating between bacterial fluid and non-bacterial fluid infections. NOVOSCOPE^® features Ultratip specialized disposable ultrasound specula tips explicitly designed for ear examinations.

The NOVOSCOPE^® represents a significant evolution from the company’s earlier approach, which provided a quantitative score to assess the likelihood of infection. . Now it identifies the type of fluid and its readings have been validated against surgical outcomes and lab analyses, such as those obtained from children undergoing tympanostomy surgery, providing medical professionals with objective, actionable data.

“Our technology allows pediatricians to make informed decisions, ultimately reducing unnecessary prescriptions and promoting antimicrobial stewardship,” says Caitlin Cameron, CEO of OtoNexus Medical Technologies.

NOVOSCOPE^® delivers precise diagnostic results within just two seconds at the push of a button. The company employed artificial intelligence (machine learning) to develop highly accurate diagnostic algorithms. Once integrated into the device, the algorithm remains static to ensure consistency in clinical environments. However, the company continuously reassesses and advances its clinical research to improve the algorithm, allowing for future updates that enhance diagnostic accuracy.

Resembling a traditional otoscope, the NOVOSCOPE^® is designed to integrate seamlessly into the pediatrician’s current workflow. It requires minimal training, enhancing efficiency for healthcare professionals, including nurses, physician assistants (PAs), and medical assistants (MAs), making it a versatile tool across the healthcare team. The device’s data automatically transfers results to the Electronic Medical Records (EMR), populating results to create a comprehensive digital record for future reference.

The value proposition for NOVOSCOPE^® extends beyond diagnosing otitis media. It enhances physician efficiency by providing an intuitive, easy-to-use solution supporting clinical decision-making. With access to real-time, actionable data indicating the nature of the infection, pediatricians can engage in more informed conversations with parents, promoting consensus on treatment options. This approach builds trust and confidence in the proposed treatment plan, whether it involves withholding antibiotics for a viral infection or prescribing them for a bacterial one.

Our technology allows pediatricians to make informed decisions, ultimately reducing unnecessary prescriptions and promoting antimicrobial stewardship

OtoNexus Medical Technologies’ NOVOSCOPE^® is set to transform the diagnosis of otitis media. OtoNexus achieved a significant milestone by being selected for the FDA’s Safer Technologies Program (STeP), a pioneering initiative designed to expedite the development and review of innovative medical devices. Devices chosen for the program demonstrate a substantial advantage over currently available alternatives, ensuring patients have timely access to breakthrough technologies. The inclusion in the STeP program highlights the potential impact of NOVOSCOPE^® on improving pediatric care and affirms the company’s commitment to advancing patient safety and antimicrobial stewardship.

Simultaneously, the company has several product line expansions in the pipeline, including several versions of NOVOSCOPE^®—from a home health version for telehealth, a global health version tailored for use in developing nations, and a veterinary version for animal health.

As the company continues to push the boundaries of innovation and expand its product portfolio, it envisions its technology reshaping the diagnosis of otitis media. The versatility and precision of its diagnostic capabilities hold promise for applications beyond healthcare, including manufacturing and food production. By anticipating diverse industry needs, the company positions itself to extend its impact, offering solutions that transcend traditional healthcare boundaries to drive advancements across multiple fields.